D
Gyre Therapeutics, Inc. GYRE
$8.68 -$2.53-22.57% NASDAQ
Recommendation
Prev Close
$8.68
Volume
2,106,389
Avg Vol (90D)
151,970
Market Cap
$764.72M
Dividend & Yield
--
52-Week Range
$6.11 - $19.00
P/E (TTM)
436.18
EPS (TTM)
$0.0199
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Gyre Therapeutics (GYRE, $8.68) price exceeded its 50-day Moving Average on May 23, 2025
5/24/2025 - Tickeron - Stocks
Gyre Therapeutics (GYRE, $8.68) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 23, 2025
5/24/2025 - Tickeron - Stocks
Gyre Therapeutics (GYRE, $8.68) entered Downtrend as Momentum indicator drops below 0 level on May 23, 2025
5/24/2025 - Tickeron - Stocks
Gyre Therapeutics (GYRE) Launches $20 Million Public Offering
5/23/2025 - GuruFocus
Gyre Therapeutics slumps 16%, prices $20M stock offering
5/23/2025 - Seeking Alpha - Healthcare
Gyre Therapeutics slumps 16%, prices $20M stock offering
5/23/2025 - SeekingAlpha.com: All News
Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00
5/23/2025 - TipRanks Financial Blog
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
5/23/2025 - Globe Newswire
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial GYRE Stock News
5/22/2025 - GuruFocus
Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth GYRE ...
5/22/2025 - GuruFocus
Gyre Therapeutics announces Hydronidone trial met primary endpoint
5/22/2025 - The Fly
Gyre Therapeutics commences underwritten public offering
5/22/2025 - Seeking Alpha - Healthcare
Gyre Therapeutics announces common stock offering, no amount given
5/22/2025 - TipRanks Financial Blog
Gyre Therapeutics announces common stock offering, no amount given
5/22/2025 - The Fly
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
5/22/2025 - Globe Newswire
Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
5/22/2025 - Globe Newswire
Gyre Therapeutics (GYRE, $10.39) RSI Indicator left the overbought zone on May 14, 2025
5/15/2025 - Tickeron - Stocks
Gyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Still a Buy?
5/14/2025 - MarketBeat
GYRE Makes Bullish Cross Above Critical Moving Average
5/13/2025 - Market News Video
Gyre Therapeutics (GYRE, $10.83) RSI Indicator left the overbought zone on May 12, 2025
5/13/2025 - Tickeron - Stocks
Gyre Therapeutics (GYRE, $10.83) price may drop as it broke higher Bollinger Band on May 12, 2025
5/13/2025 - Tickeron - Stocks
Gyre Therapeutics Reports Q1 2025 Financial Results
5/10/2025 - TipRanks Financial Blog
Gyre Therapeutics GAAP EPS of $0.00 misses by $0.03, revenue of $22.1M misses by $6.3M
5/9/2025 - SeekingAlpha.com: All News
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update ...
5/9/2025 - GuruFocus
Gyre Therapeutics Inc Reports Q1 2025 Revenue of $22. ...
5/9/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$100.64M
EBITDA (TTM)
$12.13M
EBIT (TTM)
$10.43M
Net Income (TTM)
$7.25M
Balance Sheet
Total Assets (Q)
$129.79M
Total Debt (Q)
$1.59M
Total Liabilities (Q)
$25.49M
Book Value Per Share (Q)
$0.7773
Cash Flow
Cash from Operations (TTM)
-$6.65M
Cash from Investing (TTM)
-$10.70M
Cash from Financing (TTM)
$2.79M
Net Change in Cash (TTM)
-$14.74M
Filings
Filing Date
Friday, May 9, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-20.66%
30-Day Total Return
15.43%
60-Day Total Return
-25.17%
90-Day Total Return
-20.59%
Year to Date Total Return
-27.67%
1-Year Total Return
-27.61%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $6.11
52-week High
Nov 12, 2024 - $19.00
Valuation
Market Cap
$764.72M - Small Cap
Enterprise Value
$772.59M
Price/Sales (TTM)
8.80
Price/Book (Q)
11.17
Dividends and Shares
Shares Outstanding
101.97M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.gyretx.com
Phone Number
(619) 949-3681
Address
12770 High Bluff Drive
San Diego, CA 92130
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed